These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3216039)

  • 1. Pharmacokinetic profile of OPC-8212 in humans: a new, nonglycosidic, inotropic agent.
    Ohnishi A; Ishizaki T
    J Clin Pharmacol; 1988 Aug; 28(8):719-26. PubMed ID: 3216039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of intravenous OPC-18790 in humans: a novel nonglycosidic inotropic agent.
    Ohnishi A; Toyoki T; Ohno T; Takeshige Y; Fujita T; Kodama K; Mishima M; Hirayama A; Kitani M; Miyamoto G
    J Clin Pharmacol; 1994 Feb; 34(2):176-83. PubMed ID: 8163718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women.
    Cristina Castelli M; Bhaskar S; Lippman J
    Clin Ther; 2013 Jun; 35(6):862-9. PubMed ID: 23795577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans.
    Ohnishi A; Ko Y; Fujihara H; Miyamoto G; Okada K; Odomi M
    J Clin Pharmacol; 1993 Mar; 33(3):230-8. PubMed ID: 8385161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.
    Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
    Clin Ther; 2016 Jan; 38(1):39-52. PubMed ID: 26581327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone.
    Frye RF; Tammara B; Cowart TD; Bramer SL
    J Clin Pharmacol; 1999 Nov; 39(11):1177-83. PubMed ID: 10579149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration.
    Stass H; Kubitza D; Schühly U
    Clin Pharmacokinet; 2001; 40 Suppl 1():1-9. PubMed ID: 11352436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
    Jones A; Wang-Smith L; Pham T; Laliberte K
    J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a new positive inotropic agent, 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212), in the rat, rabbit, beagle dog and rhesus monkey.
    Miyamoto G; Sasabe H
    Arzneimittelforschung; 1984; 34(3A):394-402. PubMed ID: 6540095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study.
    Zhou H; Wu G; Hu X; Zhu M; Zhai Y; Liu J; Shentu J; Wu L
    Clin Ther; 2015 Jun; 37(6):1292-300. PubMed ID: 25869627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers.
    van Marle S; van Vliet A; Sollie F; Kambayashi Y; Yamada-Sawada T
    Int J Clin Pharmacol Ther; 2005 Jun; 43(6):282-93. PubMed ID: 15968885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety, and tolerability of flosequinan in patients with hepatic dysfunction.
    Hinson JL; Hind ID; Weidler DJ
    J Pharm Sci; 1994 Mar; 83(3):382-5. PubMed ID: 8207686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.
    Cheng H; Leff JA; Amin R; Gertz BJ; De Smet M; Noonan N; Rogers JD; Malbecq W; Meisner D; Somers G
    Pharm Res; 1996 Mar; 13(3):445-8. PubMed ID: 8692739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction of sparfloxacin and digoxin.
    Johnson RD; Dorr MB; Hunt TL; Conway S; Talbot GH
    Clin Ther; 1999 Feb; 21(2):368-79. PubMed ID: 10211539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.